BioSpace News Archive

Novel, plasmid-free manufacturing system reduces cost of goods and improves AAV quality to enable development of safer gene therapies

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Fall 2020 Conference on Wednesday, September 23rd at 12:15 p.m. Eastern Time.

Cognizant’s Expert Support of Medical Device Organizations and Digital Transformation Capabilities Cited in New PEAK Matrix Assessment

Dallas-based UT Southwestern Medical Center’s Simmons Cancer Center, one of the elite centers in the country for patient care, research and education joins Caris’ best-in-class collaborative research network focused on expanding the application of precision medicine in oncology

SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial stage biotech company, CEO Denis Corin, who discusses initial commercial uptake of Strontium89, its FDA approved drug for the non-opioid treatment of metastatic cancer in the bone. Corin added context and his insights into the other Company news regarding the GMP production contract has been init

MicroVention, Inc., a U.S. based subsidiary of Terumo and leading global neurovascular company, announced today the appointment of a new President and CEO, Mr. Carsten Schroeder . The MicroVention acting President and CEO, Kazuaki Kitabatake , who has

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule

Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) Application for GEN-011, an adoptive T cell therapy targeting neoantigens and designed to improve upon the limitations of TIL and TCR therapies. The IND allows Genocea to initiate a Phase 1/2a cl

Daewoong Pharmaceutical Co., Ltd. today commented on the decision by the United States International Trade Commission to comprehensively reconsider a judge’s initial determination in the case. Daewoong and its partner Evolus, Inc. contend the judge’s initial determination contained significant legal and factual errors and, if adopted as final by the ITC, risks setting dangerous policy precedents. The ITC has announced it wil

Emmetrope Ophthalmics LLC (“Emmecell”), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of eye diseases, today announced that the